Table 4.
Time trend analysis of ASMR for cancer attributable to high body mass index from 1990 to 2019 by cancer type.
| Cancer type | Trend 1 | Trend 2 | Trend 3 | AAPC | |||
|---|---|---|---|---|---|---|---|
| Period | APC | Period | APC | Period | APC | ||
| Esophageal cancer | 1990–2005 | 1.7 (1.6, 1.8) | 2005–2015 | −1.0 (−1.3, −0.8) | 2015–2019 | 1.1 (0.1, 2.1) | 0.7 (0.5, 0.8) |
| Breast cancer | 1990–2001 | 1.0 (0.8, 1.1) | 2001–2004 | 1.4 (−0.8, 3.7) | 2004–2019 | 0.7 (0.7, 0.8) | 0.9 (0.7, 1.1) |
| Gallbladder and biliary tract cancer | 1990–2007 | −0.2 (−0.3, −0.1) | 2007–2016 | −0.8 (−1.1, −0.4) | 2016–2019 | 1.1 (−0.6, 2.9) | −0.2 (−0.4, 0) |
| Liver cancer | 1990–1999 | 3.1 (2.8, 3.3) | 1999–2004 | −4.2 (−4.9, −3.5) | 2004–2019 | 1.2 (1.1, 1.3) | 0.8 (0.7, 1.0) |
| Uterine cancer | 1990–2000 | 0 (−0.3, 0.2) | 2000–2003 | 0.7 (−2.5, 4.0) | 2003–2019 | −0.2 (−0.4, −0.1) | −0.1 (−0.4, 0.3) |
| Pancreatic cancer | 1990–2012 | 1.5 (1.4, 1.6) | 2012–2017 | 0.7 (−0.6, 2.0) | 2017–2019 | 2.4 (−1.8, 6.7) | 1.4 (1.1, 1.8) |
| Multiple myeloma | 1990–1999 | 2.2 (1.3, 3.2) | 1999–2004 | −0.1 (−3.3, 3.1) | 2004–2019 | 0.9 (0.5, 1.4) | 1.1 (0.5, 1.8) |
| Colon and rectum cancer | 1990–2004 | 1.0 (0.9, 1.2) | 2004–2016 | 0.2 (0, 0.4) | 2016–2019 | 1.2 (−0.2, 2.6) | 0.7 (0.6, 0.9) |
| Thyroid cancer | 1990–1992 | 13.8 (3.0, 25.7) | 1992–2009 | 0.1 (−0.3, 0.4) | 2009–2019 | 2.3 (1.5, 3.1) | 1.7 (1.0, 2.5) |
| Kidney cancer | 1990–1993 | 3.5 (2.1, 4.9) | 1993–2008 | 1.1 (1.0, 1.2) | 2008–2019 | 0.3 (0.2, 0.5) | 1.1 (0.9, 1.2) |
| Ovarian cancer | 1990–2010 | 0 (−0.2, 0.2) | 2010–2016 | 0.8 (−0.7, 2.4) | 2016–2019 | 3.7 (0.1, 7.3) | 0.5 (0.1, 1.0) |
| Non-Hodgkin lymphoma | 1990–1998 | 2.5 (2.0, 3.1) | 1998–2011 | 0.1 (−0.3, 0.4) | 2011–2019 | 0.9 (0.4, 1.5) | 1.0 (0.7, 1.2) |
| Leukemia | 1990–1992 | 1.7 (−1.8, 5.3) | 1992–2003 | 0.6 (0.4, 0.9) | 2003–2019 | 0.2 (0, 0.3) | 0.4 (0.2, 0.7) |
AAPC, average annual percentage change; APC, annual percentage change; ASMR, age-standardized.